Florfinasone Otic Adds Triple-Action Prescription Treatment for Canine Ear Infections

Florfinasone™ Otic has entered the veterinary market as a prescription combination treatment for canine otitis externa, bringing antibacterial, antifungal and anti-inflammatory activity together in a single-dose otic formulation.

The formulation combines three active ingredients: florfenicol, an antibacterial agent; terbinafine, an antifungal; and mometasone furoate, a corticosteroid with anti-inflammatory activity. Each 1 mL single-use dropperette contains 16.6 mg of florfenicol, 14.8 mg of terbinafine and 2.2 mg of mometasone furoate. The combination is intended to address bacterial and yeast-associated infection alongside inflammation in the external ear canal.

The product is indicated for the treatment of otitis externa in dogs associated with susceptible strains of Staphylococcus pseudintermedius and Malassezia pachydermatis. The formulation is supplied in single-dose dropperettes, with cartons containing two or ten units. Its prescription status means administration is restricted to use under veterinary direction.

Animal Drugs at FDA

+1

The combination approach reflects a common clinical challenge in canine ear disease. Otitis externa may involve bacterial or yeast overgrowth, inflammation and underlying predisposing factors. A product that combines antimicrobial and anti-inflammatory components can address multiple aspects of the condition, although accurate diagnosis remains essential to select appropriate treatment.

Clinical considerations

The product label requires veterinary personnel to clean and dry the external ear canal and verify that the tympanic membrane is intact before administration. The label also includes precautions related to potential eye exposure during administration, particularly if a dog shakes its head after treatment. The treatment is for dogs only and is not intended for cats.

For veterinary practices, fixed-combination otic products can offer a convenient administration format, particularly when a single treatment dose is appropriate. Their use must nevertheless be guided by clinical examination, the suspected or confirmed organisms, ear-drum integrity and the animal’s treatment history.

Market significance

The introduction of Florfinasone Otic adds another combination option to the canine dermatology market. Its commercial relevance will depend on veterinary familiarity, availability, pricing and how it fits alongside existing otic therapies. No independent comparative efficacy or market-uptake data were identified in the sources reviewed for this article.